Johnlim Samba CEO: "We Will Emerge as a True End-to-End Solution Provider"

John Lim, CEO of Samsung Biologics (Photo by Samsung Biologics)

[Asia Economy Reporter Chunhee Lee] "As a leader in the Contract Manufacturing Organization (CMO) sector, we will transform into a true 'end-to-end' solution provider, covering everything from Contract Development Organization (CDO) to finishing processes," said John Rim, CEO of Samsung Biologics.

Samsung Biologics announced on the 16th that John Rim, CEO, delivered the opening address at 'Bio Digital 2021,' the world's largest bio event, on the 15th (local time).

Bio Digital 2021 is the 28th edition of the 'BIO International Convention,' held online this year. The event opened on the 10th and will run for a week until the 18th. Samsung Biologics has participated with a dedicated booth for nine consecutive years from its founding year in 2011 through 2019. Since last year, when the event shifted online due to the COVID-19 pandemic, the company has maintained connections with clients through a virtual exhibition hall.

On the 15th, CEO John Rim served as the opening speaker for a presentation session hosted by Richard Haas, President of the U.S. Council on Foreign Relations, and Jeremy Levin, CEO of Ovid Therapeutics, introducing the achievements Samsung Biologics has accumulated over the past decade, its business expansion plans, and vision to industry leaders.

He stated, "Samsung Biologics is supporting the aseptic filling and finishing of Moderna's 'messenger ribonucleic acid (mRNA)-1273' vaccine based on high quality, speed, and efficiency to overcome the global crisis," and emphasized, "As a leader in the CMO field, we are striving to become a true end-to-end solution provider, from CDO to bio-safety testing, aseptic filling, and finishing processes." He added, "With the mission to enrich and advance the lives of all humanity through technology and innovation, we will bring you greater success faster."

During the event, Samsung Biologics will also participate in various programs to demonstrate its status as an industry-leading company. Sam McAuliffe, Executive Vice President of Samsung Biologics, will present strategies for overcoming COVID-19 through an online video, and Group Leader Junyoung Jang will participate in a one-on-one interview with Tony Gill, a bio forum leader, discussing bio market trends, Contract Development and Manufacturing Organization (CDMO) industry trends, and Samsung Biologics’ differentiated CDMO services.

This content was produced with the assistance of AI translation services.